{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:47:18Z","timestamp":1793832438334,"version":"4.6.1"},"reference-count":50,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141116"],"award-info":[{"award-number":["82141116"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300106"],"award-info":[{"award-number":["82300106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473015"],"award-info":[{"award-number":["82473015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Pujiang Programme","award":["2023PJD054"],"award-info":[{"award-number":["2023PJD054"]}]},{"name":"Shanghai \"Rising Stars of Medical Talents\u201d Youth Development Program\u2014Youth Medical Talents \u2013 Specialist Program","award":["SHWSRS (2024)070"],"award-info":[{"award-number":["SHWSRS (2024)070"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,6,11]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Osteosarcoma (OS) with pulmonary metastasis remains challenging due to limited treatment options and the immunosuppressive nature of the tumor microenvironment (TME). Bacteria-mediated cancer therapy has emerged as a promising strategy for solid tumors but often suffers from limited efficacy due to the immunosuppressive TME, which restricts the intensity and durability of the antitumor immune response. To overcome these challenges, we engineered a novel Salmonella strain, VNP20009-CCL2-CXCL9 (VNP-C-C), leveraging the intrinsic tumor tropism of\n                      <jats:italic>Salmonella typhimurium<\/jats:italic>\n                      VNP20009 (VNP) and improving immune modulation through the recruitment of effector immune cells into the TME by the chemokines CCL2 and CXCL9.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>VNP-C-C was genetically engineered through electroporation of Plac-CCL2-CXCL9 plasmid and validated in vitro. Its antitumor efficacy, immune regulation capacity and immunomodulatory mechanisms were evaluated in vitro by using OS cell lines and immune cells (dendritic cells (DCs) and macrophages (M\u03c6s)) and in vivo by using both immunocompromised and immunocompetent mouse models of OS lung metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>VNP-C-C effectively accumulated within tumors, triggering immunogenic cell death and subsequently activating the cyclic GMP-AMP synthase (cGAS)\/stimulator of interferon genes (STING) pathway, thereby robustly promoting type I interferon secretion. The chemokines CCL2 and CXCL9 amplified the immune response by recruiting DCs, M\u03c6s, and T cells to the TME. This orchestrated immune modulation reprogrammed tumor-associated macrophages to an antitumor phenotype, induced DCs maturation, significantly increased T-cell infiltration and activation within tumors, and promoted systemic T-cell memory formation in peripheral lymphoid organs. These effects collectively inhibited OS lung metastasis progression and provided survival benefits in mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The engineered bacterial strain VNP-C-C effectively converts the OS lung metastatic TME into a pro-inflammatory milieu, thereby stimulating robust innate and adaptive immune responses. This offers a highly promising therapeutic avenue for OS lung metastasis with considerable translational potential in cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012269","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:55:37Z","timestamp":1751410537000},"page":"e012269","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS\/STING axis in osteosarcoma lung metastasis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-3905","authenticated-orcid":false,"given":"Ruixuan","family":"Liu","sequence":"first","affiliation":[{"name":"Orthopedics, Ruijin Hospital, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-7396","authenticated-orcid":false,"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Orthopedics, Ruijin Hospital, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Neurology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhusheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Orthopedics, Ruijin Hospital, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Neurosurgery, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Tao","sequence":"additional","affiliation":[{"name":"Neurosurgery, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ogando-Rivas","sequence":"additional","affiliation":[{"name":"Neurosurgery, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Castillo","sequence":"additional","affiliation":[{"name":"Pediatrics, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Orthopedics, Ruijin Hospital, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2026052108152645000_13.7.e012269.1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2026052108152645000_13.7.e012269.2","unstructured":"Society AC . Living as an osteosarcoma survivor. n.d. Available: https:\/\/www.cancer.org\/cancer\/types\/osteosarcoma\/after-treatment\/follow-up.html"},{"key":"2026052108152645000_13.7.e012269.3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09042-6"},{"key":"2026052108152645000_13.7.e012269.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.09.042"},{"key":"2026052108152645000_13.7.e012269.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02105-9","article-title":"Advances on immunotherapy for osteosarcoma","volume":"23","author":"Yu","year":"2024","journal-title":"Mol Cancer"},{"key":"2026052108152645000_13.7.e012269.6","doi-asserted-by":"crossref","unstructured":"Coley WB . The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991;3\u201311.","DOI":"10.1097\/00003086-199101000-00002"},{"key":"2026052108152645000_13.7.e012269.7","doi-asserted-by":"crossref","unstructured":"Liu Y , Niu L , Li N , et al . Bacterial\u2010Mediated Tumor Therapy: Old Treatment in a New Context. Adv Sci (Weinh) 2023;10. doi:10.1002\/advs.202205641","DOI":"10.1002\/advs.202205641"},{"key":"2026052108152645000_13.7.e012269.8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2018.15","article-title":"Oncolytic viruses prime antitumour immunity","volume":"15","author":"Romero","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052108152645000_13.7.e012269.9","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0196-9"},{"key":"2026052108152645000_13.7.e012269.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0070-z"},{"key":"2026052108152645000_13.7.e012269.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.008"},{"key":"2026052108152645000_13.7.e012269.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50950-5","article-title":"Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella","volume":"15","author":"Nguyen","year":"2024","journal-title":"Nat Commun"},{"key":"2026052108152645000_13.7.e012269.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.add9667"},{"key":"2026052108152645000_13.7.e012269.14","doi-asserted-by":"publisher","DOI":"10.1086\/315497"},{"key":"2026052108152645000_13.7.e012269.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-48606-5","article-title":"Stimulation of tumoricidal immunity via bacteriotherapy inhibits glioblastoma relapse","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"2026052108152645000_13.7.e012269.16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202719119","article-title":"Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth","volume":"119","author":"Ahmed","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026052108152645000_13.7.e012269.17","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1021\/jacs.2c07287","article-title":"Combined Cellular Thermometry Reveals That Salmonella typhimurium Warms Macrophages by Inducing a Pyroptosis-like Phenotype","volume":"144","author":"Wu","year":"2022","journal-title":"J Am Chem Soc"},{"key":"2026052108152645000_13.7.e012269.18","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12203"},{"key":"2026052108152645000_13.7.e012269.19","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1016\/j.apsb.2022.05.006","article-title":"Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhi murium VNP20009 in anti-PD1 therapy against melanoma","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"2026052108152645000_13.7.e012269.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.142"},{"key":"2026052108152645000_13.7.e012269.21","first-page":"1594","article-title":"A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001","volume":"12","author":"Cunningham","year":"2001","journal-title":"Hum Gene Ther"},{"key":"2026052108152645000_13.7.e012269.22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41591-019-0498-z","article-title":"Programmable bacteria induce durable tumor regression and systemic antitumor immunity","volume":"25","author":"Chowdhury","year":"2019","journal-title":"Nat Med"},{"key":"2026052108152645000_13.7.e012269.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01132-2"},{"key":"2026052108152645000_13.7.e012269.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0244-x"},{"key":"2026052108152645000_13.7.e012269.25","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200844","article-title":"STING agonist promotes CAR T cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2021","journal-title":"J Exp Med"},{"key":"2026052108152645000_13.7.e012269.26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature New Biol"},{"key":"2026052108152645000_13.7.e012269.27","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn6612","article-title":"Selective STING stimulation in dendritic cells primes antitumor T cell responses","volume":"8","author":"Jneid","year":"2023","journal-title":"Sci Immunol"},{"key":"2026052108152645000_13.7.e012269.28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41551-023-01073-7","article-title":"Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway","volume":"8","author":"An","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"2026052108152645000_13.7.e012269.29","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat8657","article-title":"cGAS in action: Expanding roles in immunity and inflammation","volume":"363","author":"Ablasser","year":"2019","journal-title":"Science"},{"key":"2026052108152645000_13.7.e012269.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113407","article-title":"Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus","volume":"12","author":"Froechlich","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026052108152645000_13.7.e012269.31","doi-asserted-by":"crossref","first-page":"22153","DOI":"10.1021\/acsnano.4c05483","article-title":"Hypoxia Reversion and STING Pathway Activation through Large Mesoporous Nanozyme for Near-Infrared-II Light Amplified Tumor Polymetallic-Immunotherapy","volume":"18","author":"Qu","year":"2024","journal-title":"ACS Nano"},{"key":"2026052108152645000_13.7.e012269.32","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202309994","article-title":"Chimeric Peptide-Engineered Self-Delivery Nanomedicine for Photodynamic-Triggered Breast Cancer Immunotherapy by Macrophage Polarization","volume":"20","author":"Liu","year":"2024","journal-title":"Small"},{"key":"2026052108152645000_13.7.e012269.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.012"},{"key":"2026052108152645000_13.7.e012269.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115318"},{"key":"2026052108152645000_13.7.e012269.35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087385","article-title":"CCL2-Mediated Stromal Interactions Drive Macrophage Polarization to Increase Breast Tumorigenesis","volume":"24","author":"Archer","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026052108152645000_13.7.e012269.36","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01478-6","article-title":"Metabolism, metabolites, and macrophages in cancer","volume":"16","author":"Li","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026052108152645000_13.7.e012269.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026052108152645000_13.7.e012269.38","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq6509","article-title":"CXCL9 and CXCL10 bring the heat to tumors","volume":"7","author":"Reschke","year":"2022","journal-title":"Sci Immunol"},{"key":"2026052108152645000_13.7.e012269.39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000599","article-title":"Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-\u03b3, CXCL9 and CXCL10","volume":"8","author":"Bergamaschi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052108152645000_13.7.e012269.40","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2292"},{"key":"2026052108152645000_13.7.e012269.41","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.7150\/thno.71010","article-title":"Novel formulation of c-di-GMP with cytidinyl\/cationic lipid reverses T cell exhaustion and activates stronger anti-tumor immunity","volume":"12","author":"Yu","year":"2022","journal-title":"Theranostics"},{"key":"2026052108152645000_13.7.e012269.42","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02380-2"},{"key":"2026052108152645000_13.7.e012269.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.11.014"},{"key":"2026052108152645000_13.7.e012269.44","article-title":"Comparative evaluation of the acute toxic effects in monkeys, pigs and mice of a genetically engineered salmonella strain (VNP20009) being developed as an antitumor agent","volume":"19","author":"King C. Lee","year":"2000","journal-title":"Int J Toxicol"},{"key":"2026052108152645000_13.7.e012269.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01040-6"},{"key":"2026052108152645000_13.7.e012269.46","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.7150\/thno.87340","article-title":"Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy","volume":"13","author":"Sun","year":"2023","journal-title":"Theranostics"},{"key":"2026052108152645000_13.7.e012269.47","doi-asserted-by":"crossref","unstructured":"Liu L , Xin W , Li Q , et al . Neutrophil\u2010Mediated Tumor\u2010Targeting Delivery System of Oncolytic Bacteria Combined with ICB for Melanoma Lung Metastasis Therapy. Adv Sci (Weinh) 2023;10. doi:10.1002\/advs.202301835","DOI":"10.1002\/advs.202301835"},{"key":"2026052108152645000_13.7.e012269.48","doi-asserted-by":"crossref","first-page":"109372","DOI":"10.1016\/j.isci.2024.109372","article-title":"Oncolytic bacteria VNP20009 expressing IFN\u03b2 inhibits melanoma progression by remodeling the tumor microenvironment","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"},{"key":"2026052108152645000_13.7.e012269.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.08.090"},{"key":"2026052108152645000_13.7.e012269.50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55751-4","article-title":"Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:15:53Z","timestamp":1779376553000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2025-012269"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012269","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}